Modeling Pharmacokinetics of Doxorubicin in Multiple Myeloma Cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34892189/
Doxorubicin (DOXO) is a well-established chemotherapy drug for treatment of different tumors, ranging from breast cancer, melanoma to multiple myeloma (MM). Here, we present a coupled experimental/modeling approach to study...
Relevance: The model can be used to properly understand and guide further experimental setup, e.g., to investigate multiple myeloma cell variability among different cell lines.
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34854741/
Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma...
Conclusion/Relevance:This paper reviews the ide-cel product in terms of design, pharmacology, efficacy and toxicity as described in studies reported to date.
Absolute lymphocyte count prior lymphodepletion impacts outcomes in multiple myeloma patients treated with CAR-T cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34861455/
1 Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Key Laboratory of Bone Marrow Stem...
Conclusion: In conclusion, pre-LD ALC could be a useful indicator to predict the outcomes of CAR-T cell therapy in patients with R/R MM.
Regular Aspirin Use and Mortality in Multiple Myeloma Patients
Source : https://cebp.aacrjournals.org/content/early/2021/12/03/1055-9965.EPI-21-0946
Background: Inflammation is important in multiple myeloma (MM) pathogenesis, and regular aspirin use has been shown to confer a reduced risk of MM. The influence of aspirin on survival after...
Conclusions: Findings support the use of aspirin as a complementary strategy to enhance MM survival. Impact: Confirmation in samples that have comprehensive clinical information is encouraged.
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis - Blood Cancer Journal
Source : https://www.nature.com/articles/s41408-021-00569-2
The Mayo-2018 smoldering multiple myeloma (SMM) risk score is used routinely in the clinical setting but has only been validated at diagnosis. In SMM patients, the progression risk decreases over...
Conclusion/Relevance: In conclusion, we showed that the Mayo 2018 and IMWG 2020 risk stratification models can be applied for up to 5 years post SMM diagnosis. Furthermore, we showed that patients migrating to a higher risk category have an increased risk of progression, suggesting that if patients evolve to a high-risk score during follow-up,...